聚焦伯尔尼斯坦_泛欧制药概要:ATTR的“蛋白质扼杀”疗法——为何AZN将引领这一200亿美元的心脏市场。(Whilst ALNY’s twice yearly ‘Next Gen’ silencer nucresiran may ‘step-up’ convenience, we expect it to cannibalize Amvuttra. For nucresiran there no payaways to Sanofi (O)), which receives a blended mid-20’s royalty from sales of Amvuttra.
聚焦伯尔尼斯坦_泛欧制药概要:ATTR的“蛋白质扼杀”疗法——为何AZN将引领这一200亿美元的心脏市场。(Whilst ALNY’s twice yearly ‘Next Gen’ silencer nucresiran may ‘step-up’ convenience, we expect it to cannibalize Amvuttra. For nucresiran there no payaways to Sanofi (O)), which receives a blended mid-20’s royalty from sales of Amvuttra.
聚焦伯尔尼斯坦_泛欧制药概要:ATTR的“蛋白质扼杀”疗法——为何AZN将引领这一200亿美元的心脏市场。(Whilst ALNY’s twice yearly ‘Next Gen’ silencer nucresiran may ‘step-up’ convenience, we expect it to cannibalize Amvuttra. For nucresiran there no payaways to Sanofi (O)), which receives a blended mid-20’s royalty from sales of Amvuttra.
覆盖 2026 年,全文共 38 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了制药、伯尔尼斯坦_泛欧制药概要、ATTR的“蛋白质扼杀”疗法等议题。